Cipla receives USFDA nod to market Lanreotide injection in US market

Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market.

Powered by WPeMatico

Scroll to top